Apolipoprotein CII (apoCII) activates lipoprotein lipase (LPL). Seven residues, located on one face of a model α-helix spanning residues 59-75, are fully conserved in apoCII from ten different animal species. We have mutated these residues one by one. Substitution of Ala59 by glycine, or Thr62 and Gly65 by alanine did not change the activation, indicating that these residues are outside the LPL-binding site. Replacement of Tyr63, Ile66, Asp69 or Gln70 by alanine lowered the affinity for LPL and the catalytic activity of the LPL/apoCII complex. For each residue several additional replacements were made. Most mutants retained some activating ability, but replacement of Tyr63 by phenylalanine or tryptophan and Gln70 by glutamate caused almost complete loss of activity. All mutants bound to liposomes with similar affinity as wild-type apoCII, and they also bound with similar affinity to LPL in the absence of hydrolyzable lipids. However, the inactive mutants did not compete with wild-type apoCII in the activation assay. Therefore we conclude that the productive apoCII/LPL interaction may be dependent on substrate molecules. In summary, our data demonstrate that residues 63, 66, 69 and 70 are of special importance for the function of apoCII, but no single amino acid residue is absolutely crucial.
INTRODUCTION
Human apolipoprotein CII (apoCII) is a 79-residue protein synthesized in the intestine and liver and secreted as a surface component of chylomicrons, very low density lipoproteins and high-density lipoproteins (1) (2) (3) . ApoCII plays an important role in plasma lipid metabolism as an activator of lipoprotein lipase (LPL) (1, 4) , clearly illustrated by the severe hypertriglyceridemia that is associated with genetic deficiency of apoCII (5) . A number of natural mutations affecting the apoCII gene have been identified and characterized (6) . Most mutations reported so far result in either very low levels of plasma apoCII or major structural changes in the protein, e.g. prematurely truncated forms. A Trp26Arg mutation was recently reported to lead to apoCII deficiency, probably because of a disturbed lipid interaction of the activator (7) . This is the only example of a single point mutation in apoCII leading to loss of function, but the interpretation is not straightforward since the protein was not detectable in plasma.
The structure of full-length human apoCII in complex with SDS-micelles was recently reported based on studies by NMR (8) . The protein contains three regions with helical conformation spanning residues 16-36, 50-56 and 63-77. The lipase-activating region of apoCII has previously been localized to the C-terminal one third of the sequence, from about residue 56, while the N-terminal two thirds of the sequence is involved in lipid binding (9) (10) (11) . In most studies it has been found that apoCII causes an increase in the catalytic efficiency of LPL, and not an enhanced lipid affinity of the enzyme (10, 12) . In spite of a long history of studies on the effects of apoCII, the detailed mechanism for the activation remains unknown. It has been proposed that apoCII binds to LPL and induces conformational changes in the lipase, or changes its orientation at the lipid-water sequencing. The plasmid was transformed into E. coli BL21(DE3) to express the fusion protein S-tag-"factor Xa cleavage site"-hapoCII (117 amino acid residues in total). For production of pET-histag-hapoCII, the pET29a-hapoCII plasmid was cleaved with NdeI and EcoRI to delete the sequence encoding the S-tag and the thrombin cleavage site. The complementary oligonucleotides 5' TATGCACCATCATCATCATCATG 3' and 5' AATTCATGATGATGATGATGGTGCA 3', coding for an N-terminal 6xHis-tag, were ligated to the cleaved pET29a vector. The new construct resulted in a vector with the T7 RNA polymerase promoter and the lac operator followed by sequences coding for 6xHis-tag, Factor Xa cleavage site and human apoCII.
Site-directed mutagenesis of human apoCII
Mutant 63A was generated by overlap extension by using the polymerase chain reaction (PCR) and four different primers (Table 1 ). All other mutants were generated using Quikchange TM Site-Directed Mutagenesis Kit. The basic procedure for generation of each mutant utilizes a template vector with apoCII cDNA (pET29a-hapoCII or pEThistag-hapoCII) and two synthetic oligonucleotide primers containing the desired mutation ( Table 1) . The oligonucleotide primers, each complementary to opposite strands of the vector, were extended by Pfu Turbo DNA polymerase. All mutants were sequenced using ABI 337 DNA sequencer, Dye Terminator Cycle Sequencing Ready Reaction Kit, Perkin Elmer.
Expression and purification of wild-type and mutated human apoCII proteins
pET29-hapoCII and its mutants (A59G, T62A, Y63A, G65A, I66A, D69A and Q70A) were introduced into BL21(DE3) competent cell. Expression, purification and cleavage of the fusion proteins by factor Xa were made as described (Martinez et al., manuscript in preparation), but in LB medium.
pET-histag-hapoCII ant its mutants (Y63A, Y63T, Y63L, Y63F, Y63W, I66A, I66L,   I66V, I66F, D69A, D69S, D69N, D69E, Q70A, Q70A, Q70N, Q70E, L72A, S73A and   V74A) were transformed into Epicuran Coli  BL21-CodonPlus(DE3)-RIL competent cell. The bacteria were grown at 37°C in Terrific Broth containing kanamycin (50 µg/ml)
to an OD 600nm of 1.0. At this point the temperature was lowered to 16°C and one hour later expression of human apoCII and its variants was induced with 0.5 mM IPTG. On the next day, the bacteria were harvested by centrifugation and purified by Ni 2+ -NTA agarose as described (19) . Briefly, buffers containing 8 M urea, 0.1 M NaH 2 PO 4 , 0.01 M Tris-Cl were used to produce a stepwise gradient from pH 8.0 to pH 4.5. The fusion proteins that eluted at pH 7.2 were dialyzed for 24 hours at 4°C against ammonium bicarbonate and were then lyophilized.
High performance liquid chromatography of wild-type and mutated His-tagged human apoCII proteins
High performance ion exchange was performed on an ÄKTA purifier 900 (AmershamPharmacia) using a Mini Q PE 4.6/50 column. The fusion proteins eluted between pH 6.8 and pH 4.5 from Ni 2+ -NTA agarose were dialyzed against 6 M urea, 0.01 M Tris pH 8.2
and were filtered through a 0.2 µm filter (Gelman Sciences, 600 S, Wagner Rd, Ann
Arbor, MI 48103) before they were applied to the column at a pressure of 5 MPa. Proteins were then eluted by a linear gradient of Tris-Cl (pH 8.2) from 0.01 to 0.15 M. Remaining proteins were washed out by 1M NaCl and/or 6 M guanidinium chloride (GdmCl).
Protein concentrations in all the fractions were measured by the BCA assay. Fractions were combined and the proteins were analyzed by electrophoresis on SDS-Tricine gels and by N-terminal amino acid sequence analyses as previously described (16). Two forms of apoCII were detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) on a homemade instrument at National Institute of Chemical Physics and Biophysics, Tallinn, Estonia.
Proteins analyzed by Tricine SDS-PAGE and Western blotting
The expressed proteins were separated on Tricine -SDS-PAGE and were stained by 0.025% Serva-blue G in 10% acetic acid (19) . 
Circular dichroism
Possible global changes of the secondary structure of some of the mutated apoCIIs were investigated by measurements of far UV spectra at 25 °C on a CD6 spectrodichrograph (19) . The lipase activity is expressed in U/mg of LPL, where 1 U corresponds to release of 1 µmol fatty acid per min. For studies of competition between the wild-type apoCII and mutants for activation of LPL the experiments were carried out as described, except for the presence of 2.5 µM Q70E, Y63F or Y63W in the incubation mixture together with wild-type apoCII.
Determination of kinetic parameters from activation curves
Quinn et al. have shown that the activation of LPL by apoCII can be described by a random mechanism (20) . Based on this mechanism, the velocity of the reaction (v) at substrate saturation is expressed as
Where L corresponds to LPL and C corresponds to apo CII. 
Preparation of liposomes
Two different phospholipids were used in this study. One was 1,2-di-O-hexadecyl-snglycero-3-phosphatidylcholine, which cannot be hydrolyzed by LPL. This ether lipid was used for studies of the apoCII-LPL interaction. The other was egg yolk phosphatidylcholine, used for studies of the interaction between apoCII and lipids. For 
Determination of equilibrium dissociation constants by dansylation of apoCII
The wild-type apoCII and the mutants (His-tagged, not cleaved) were dansylated according to the procedure described in a previous study (19) . 
Binding of apoCII to liposomes
Binding of apoCII to liposomes was measured by using the change of fluorescence of the single tryptophan at residue 26 as described in our previous study (19) . The increase of fluorescence was attributed to binding of apoCII to the liposomes.
RESULTS

Expression and purification of apoCII and mutants
Comparison of the amino acid sequences of apoCII from the 10 different animal species shows that there are seven fully conserved residues in the C-terminal region (Fig. 1A ). All were located on the same side of a model α-helix spanning residue 59 to 75 (Fig. 1B) . To study the role of the conserved residues for the function of apoCII we first made substitutions with alanine using the codons GCC, GCA and GCT. Ala59 was instead substituted with glycine. The seven mutants and the wild-type apoCII were expressed using the pET29a-hapoCII vector, generating S-tagged apoCII proteins that were purified on S-protein agarose and cleaved by factor Xa (Fig. 2) .
In order to identify critical chemical groups or side chains, more mutants were generated at residues 63, 66, 69 and 70. These mutants were expressed using the pET-histaghapoCII vector and purified on Ni 2+ -NTA-agarose. When the pH of the elution buffer was decreased to 6.8 or lower, a protein with an apparent molecular weight of 26 kDa was eluted in addition to apoCII (Fig. 3) . For separation of this protein from apoCII, ionexchange chromatography on a Mini Q column was used (Fig. 4) . The contaminating protein bound stronger than apoCII to the column and was eluted by 1 M NaCl and/or 6M GdmCl (Fig. 4, inset) . N-terminal sequence analyses of the contaminant gave the sequence KVAKDLVVS, which was found to correspond to an E. Coli protein consisting of a domain homologous to FK506-binding proteins (21) . This protein is rich in potentially metal-binding amino acids, such as histidine, cysteine, and acidic amino acids, explaining why it bound very strongly to the Ni 2+ -NTA agarose. ApoCII was separated into two forms by the ion-exchange column (Fig. 4, inset) . N-terminal amino acid sequence analysis showed that they both had the same sequence, MHHHHH. Mass spectrometry revealed that there was a 260 dalton difference between the two forms. This corresponded to a lack of the last two glutamate residues at the C-terminal end (the theoretical difference is 258.2 dalton). The expressed wild-type apoCII contained more than 75% of the short form. Since the two forms of apoCII showed similar ability to activate LPL (data not shown), we used a mixture of the two forms of each expressed mutant for the following experiments. In another set of experiments we compared in detail the ability of His-tagged apoCII with apoCII purified from human plasma with regard to actvation of LPL. From these data we know that the His-tag at the N-terminus does not interfere with the activation (Shen Y, Lookene A, Vija H, Olivecrona G, data unpublished). Therefore we decided to use the His-tagged recombinant proteins without further cleavage for the present functional studies.
Activation of LPL by apoCII mutants
Substitution of Ala59 by glycine and residues Thr62, Gly65 by alanine did not have much effect on the activating ability of apoCII ( Table 2 .
To investigate whether the markedly reduced activation ability of some of the mutants was due to a major change of secondary structure, mutants Y63A, I66A, D69A and Q70A
were analyzed by CD measurements in the presence of liposomes of phosphatidylcholine (Fig. 6) . No major differences were found compared to the spectrum for wild-type apoCII.
All mutants retained the typical, largely helical, structure represented by double minima at 208 and 222 nm.
In addition to the alanine substitutions mentioned above, Tyr63 was replaced by threonine (Y63T), leucine (Y63L), phenylalanine (Y63F) and tryptophan (Y63W) to investigate the importance of the hydroxyl group and/or the aromatic ring (Fig. 7A) . The Y63F and Y63W mutants showed very low, though detectable, activation. Since the activation curves remained linear even at the maximally achievable apoCII concentrations, it was not possible to calculate K d and β for these mutants. To elucidate whether the poor activation was caused by low affinity of apoCII for LPL, or by low activity of the mutant apoCII/LPL complexes, the mutants Y63W and Y63F were mixed with wild-type apoCII in the same assay (Fig. 8) . The activity of wild-type apoCII was not affected even at a 20-fold excess of the inactive mutants. Therefore we concluded that the low activation by mutants Y63F and Y63W was mainly due to a reduced affinity for LPL. In contrast, the Y63T and the Y63L mutants were more efficient that Y63A (Fig. 7A) . The Y63T bound to LPL with K d = 1.73 µM and enhanced the catalytic activity four-fold (β= 4.0, Table 2 ).
mutant were determined with large deviation (Table 2) . Also I66A exhibited low affinity K d =3.27 µM, and the maximal activation was about 3-fold (β= 2.9). I66V was the most active among the mutants at position 66. It appeared to bind to LPL even more tightly than wild-type apoCII (K d = 0.11 µM). However, I66V could not activate LPL to the level reached with wild-type apoCII (β = 3.9). At high concentrations (>3 µM) there was even a tendency for inhibition of LPL by this mutant (Fig. 7B) .
Substitution of Asp69 by hydrophilic residues such as serine (D69S), glutamate (D69E) and asparagine (D69N) did not lead to prominent changes in the activating properties (Fig. 7C ). Effects were mainly seen on the K d values, which were increased approximately 6-fold compared to wild-type apoCII. Mutants D69S and D69E had similar β values as wild-type apoCII, but for D69N it was somewhat lower (β = 4.9). The weakest binding affinity was seen with the D69A mutant (K d =3.40 µM).
Three mutants were generated at position Gln70: Q70A, Q70N and Q70E (Fig, 7D) . The most active one was Q70N with K d = 2.07 µM and β=3.0. Both Q70A and Q70N showed lowered binding affinity to LPL and decreased maximal activation (Table 2 ). In contrast to these mutants, the Q70E mutant was completely inactive and could not compete with the wild-type apoCII in the assay (Fig. 8) . Thus, a negative charge at position 70 appeared to block binding of apoCII to LPL.
In addition to substitutions at the fully conserved residues, three mutants were generated at residue Leu72, Ser73 and Val74 by alanine replacement. These mutants bound to LPL with an apparent affinity comparable to that of wild-type apoCII and they activated the enzyme to the same extent as the wild-type apoCII did (data not shown) Thus, the structures of these three residues did not appear to be essential for the function of apoCII.
Interaction between LPL and apoCII in the absence of hydrolyzable lipids
The interaction of apoCII mutants with LPL was studied in the presence of liposomes of a non-hydrolysable lipid (1, 2-di-O-hexadecyl-sn-glycero-3-phosphatidylcholine). In these by guest on October 5, 2017
http://www.jbc.org/ Downloaded from experiments the apoCII mutants were dansylated, and their association to LPL was measured by monitoring fluorescence energy transfer from LPL tryptophans to the dansyl groups of the modified apoCII molecules. Dissociation constants (K d ') were determined for the apoCII/LPL complexes. All studied apoCII mutants appeared to bind to LPL with an affinity comparable to that of wild-type apoCII. The values for the dissociation constants were 0.3-0.8 µM (Fig. 9) . For wild-type apoCII this value was similar in the absence of liposomes (data not shown). Thus, in the absence of hydrolysable lipids the dissociation constants (K d ') did not vary as much as they did in the presence of the radiolabeled emulsion of triacylglycerols, where the K d variedIURPWR07DEOH
2). Figure 9 demonstrates that there was no correlation between the K d and K d ' values.
Interaction of apoCII with lipids
To elucidate whether the poor activation of LPL by some mutants was caused by a reduced interaction with lipids, the mutants were titrated with liposomes of phosphatidylcholine. Formation of lipsome/apoCII complexes was measured by monitoring fluorescence of the single tryptophan (Trp26) of apoCII on excitation at 280 nm. We had previously shown that on association of wild-type apoCII with liposomes, the tryptophan fluorescence increased and shifted the emission maximum from 345nm to 320 nm (19) . In the present study, we detected similar changes in the fluorescence for all of the studied apoCII mutants. Consequently, even the inactive mutants were able to interact with lipids. Apparent dissociation constants (K lip ) calculated from the titration curves, ranged between 101-420 µM (Table 2) .
DISCUSSION
The starting point for the present study was our previous observation that there are only seven fully conserved residues in the C-terminal one third of the apoCII molecule, the part to which the ability to activate LPL had previously been localized (16). This implied that the detailed structure of this region, limited to residues 59-70, was important and had therefore not changed during evolution. We generated a set of single-residue substitution mutants of human apoCII, mainly at the seven fully conserved sites. ApoCII was expressed either as a fusion protein with the S-tag or the 6xHis-tag at the N-terminal end.
The expressed apoCII appeared in two forms, one of which was due to truncation of the last two amino acid residues at the C-terminus (Glu78-Glu79). Although the short form in some cases constituted about 75% of the total apoCII protein, we did not further separate the individual forms since both were shown to activate LPL. Based on sequence comparisons of apoCII from different animal species we had previously concluded that the negatively charged residues (Glu78-Glu79) in the C-terminal end of human apoCII are not important for the activation (16). This was further supported by the present findings with the recombinant, truncated forms.
Effects of mutations
There was little or no effect of some of the presently investigated mutations on the secondary structure of apoCII. We can, however, not absolutely exclude conformational effects for some of the other mutants, which were not produced in sufficient amounts for CD measurements. However, theoretical structure prediction using several available computer programs did not indicate major changes for any of the mutants studied here.
To investigate if the mutations affected formation of the apoCII/ LPL complex, the catalytic power of the complex, or both, we derived two kinetic parameters; the apparent dissociation constant K d and the activation factor β. The aim was to test the hypothesis that the LPL-interaction domain of apoCII contains two regions: one contributing mainly to activation, while the other is mainly responsible for binding of apoCII to LPL (22) . For most of our mutants, however, both parameters were affected, indicating that discrimination between these functional parts of apoCII was not possible. For residue Asp69, mutants D69S, D69E and D69N did not show very dramatic changes in the activating ability, suggesting that apoCII may tolerate some variation in hydrophilic residues at this position. The main effect was an increase in the K d values. The D69S mutant was practically as efficient as the D69E mutant. Thus, a negative charge at this position did not seem to play a crucial role. In contrast to hydrophilic residues, substitution with alanine caused a more pronounced decrease in apparent binding affinity.
One of the most dramatic effects on activation was obtained by substitution of Gln70 by glutamate, indicating that the corresponding binding region in LPL is probably negatively charged. Also the Q70N mutant was rather inefficient, demonstrating that the additional carbon in the side chain of the glutamine residue is probably important for the interaction with LPL. Substitution with alanine decreased both the binding affinity (K d ) and activation ability (β). Thus, not only the amide group in the side chain of residue 70, but also the length of the carbon side chain was important for the function.
LPL interactions
To further characterize the properties of our mutants, we studied the apoCII-LPL interaction in the absence of hydrolyzable lipids. In the system with ether phospholipids the mutants did not show significant differences with regard to LPL affinity. These results are in conflict with the apparent LPL affinities from the activation experiments (K d ),
where several of the mutants showed little or no activation. The competition experiments
showed that the low-activity mutants could not compete with wild-type apoCII for binding to LPL, even at a 20-fold higher concentration. Thus, the apoCII/LPL complex observed in the absence of hydrolyzable lipid may not be the true functional complex that can hydrolyze lipids at optimal rate. One explanation could be that the lipid substrate is needed for induction of the right conformation of either LPL or apoCII, and that some of the mutations affected this interaction. It is, unfortunately, not possible to study the interaction by fluorescence with a hydrolysable lipid. The substrate would almost immediately be consumed by the high amounts of lipase needed for the experiments.
Recently it was reported that the synthetic apoCII fragment 39-62 activates LPL to the same extent as full-length apoCII (24) . These data cannot be understood from our present and previous experiences. In our study, this region is intact in all affected mutants. Still their ability to activate LPL was severely reduced or absent. Therefore, the proposed region cannot be crucial for activation, at least not as part of native apoCII. It is possible that the peptide, by non-specific effects, causes an increase in LPL activity. From previous experiments the activation seems to be specific and similar effects have not been found by other peptides. We cannot exclude that the LPL-binding site is extended towards the N-terminal end to also involve residues 59 and 62. These residues were only substituted by glycine and alanine, respectively, with little change in the activation.
Considering the evolutionary conservation of these residues, and their location preceding the third α-helix (8), it is possible that other substitutions would have had effects.
Lipid interactions
The investigation of the apoCII-liposome interaction showed that all mutants had lipidbinding affinities comparable to that of wild-type apoCII. Thus, the loss or reduction in by guest on October 5, 2017 http://www.jbc.org/ Downloaded from the activation ability of some of the mutants was not due to reduced ability to interact with lipid/water interfaces. This is consistent with the previous observations that the Nterminal domain of apoCII is the part mainly responsible for binding to lipids (9) (10) (11) . The mutations could, however, still affect details in the steric arrangement of apoCII at the lipid/water interface ways that were not detectable by the methods used here to measure lipid interaction.
ApoCII-binding site
It is still not clear where the apoCII-binding site is located on LPL. Studies with lipase chimeras of LPL and hepatic lipase suggest that apoCII binds to the N-terminal folding region of LPL (25, 26) . It was also suggested that apoCII interacts simultaneously with regions located in the N-and C-terminal domains of opposing subunits of the LPL dimer outside the LPL-interaction site, even though residue 73 is situated on the same side of the α-helix as residues 69 and 70 (8) . Taken together, multiple residues (Tyr63, Ile66, Asp69, Gln70) are involved in formation of the LPL-binding site of apoCII, but no single amino acid was absolutely crucial for the activation. 
Fig. 2. Analysis of S-tagged apoCII on Tricine-SDS-PAGE
The wild-type (WT) and mutant apoCII proteins were purified on S-protein agarose and repurified by passage over the same column after cleavage by factor Xa. Panel A shows a gel stained by Serva Blue G. Panel B shows a Western blot of the same fractions as in panel A using rabbit anti-human apoCII serum. 
Fig. 4. Purification of His-tagged wild-type apoCII by ion-exchange chromatography and analysis on Tricine-SDS-PAGE
The fraction eluted from Ni 2+ -NTA-agarose column at pH 6.8 (see Fig. 3 ) was applied on a Mini-Q column. The chromatogram shows the separation of the two forms of apoCII.
The inset shows the analysis of the fractions on Tricine-SDS-PAGE. Lanes: Mw -low molecular weight markers; a.s.-applied sample; b.t.-break through (material that was not bound to Mini-Q); fractions that were run on gel are shown by numbers; concentrations of NaCl and GdmCl used for elution were 1 M and 6 M, respectively. 
